‘Pharmaceutical companies stand to lose patent monopolies that cover a number of individual compounds within a broader chemical formula if they cannot show a plausible link between the compounds covered by the patent and a technical contribution to treatment claimed in the patent, the High Court has confirmed.’
OUT-LAW.com, 4th December 2014
Source: www.out-law.com
